Compare ECBK & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECBK | ANVS |
|---|---|---|
| Founded | 1919 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 111.3M |
| IPO Year | N/A | 2020 |
| Metric | ECBK | ANVS |
|---|---|---|
| Price | $17.38 | $3.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 14.0K | ★ 4.0M |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.95 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $29,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.49 | ★ N/A |
| Revenue Growth | ★ 20.84 | N/A |
| 52 Week Low | $12.56 | $1.11 |
| 52 Week High | $17.75 | $6.37 |
| Indicator | ECBK | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 51.37 |
| Support Level | $16.66 | $4.12 |
| Resistance Level | $17.55 | $4.64 |
| Average True Range (ATR) | 0.36 | 0.51 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 97.98 | 7.78 |
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.